Clarametyx Biosciences Inc.

About Clarametyx Biosciences Inc.

Clarametyx Biosciences is a clinical stage biopharmaceutical company focused on developing novel immune-enabling therapies to combat challenging bacterial biofilm-related chronic respiratory diseases and inflammation. Their mission is to address the burden of biofilm-mediated infections and resulting conditions like bronchiectasis.

Products & Services

CMTX-101:An investigational drug aimed at treating infections associated with cystic fibrosis and other respiratory diseases, currently under clinical trials with FDA Fast Track and Qualified Infectious Disease Product designations.

Therapeutics:Innovative therapies targeting bacterial biofilms in respiratory diseases.

Vaccination:Development of vaccination strategies to prevent biofilm-related infections.

Specialties

Immune-enabling therapies Anti-biofilm therapies Chronic respiratory disease treatment Vaccine development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 33000000 MR: - FA: $33M FAN: 33000000	D: 2024-01-05 FD: 2024-01-05	7 investors

Series A Latest

2024-01-05

$33.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Richards

Chief Executive Officer

V

Veronica L. Hall

Chief Operating Officer

C

Charles McOsker

Co-founder & Chief Scientific Officer

S

Steve St. Onge

Senior Vice President of Corporate Development

T

Teresa Byrne

VP, Clinical Operations

J

James Rogers

Director, Project Operations

View 25 more team members with Pro

Unlock Full Team Directory

Recent News